SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2003 ---------------------- COMMISSION FILE NUMBER 1-12584 DELAWARE SHEFFIELD PHARMACEUTICALS, INC. 13-3808303 (State of other jurisdiction of (Exact name of registrant as specified (I.R.S. Employer incorporation or organization) in its charter) Identification No.)
3136 Winton Road South, Suite 201, Rochester, New York 14623 - ------------------------------------------------------ ----- (Address of principal executive officers) (Zip Code) Registrant's telephone number, including area code (585) 292-0310 ---------------------- 14528 South Outer Forty Road, Suite 205, St. Louis, Missouri 63017 ------------------------------------------------------ ----- (Former name or former address, if changed since last report) ITEM 5. OTHER EVENTS On January 24, 2003, Sheffield Pharmaceuticals, Inc., a Delaware corporation, issued a press release, a copy of which is attached hereto as Exhibit 99.3 and is incorporated herein by reference. ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS (c) Exhibits Exhibit Number Description 99.3 Press Release dated January 24, 2003 issued by Sheffield Pharmaceuticals, Inc. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SHEFFIELD PHARMACEUTICALS, INC. Dated: January 28, 2003 By: /s/ Scott A. Hoffmann ------------------------------------- Scott A. Hoffmann Vice President and Chief Financial Officer